Shanghai, China – Recently, Shanghai Municipal Commission of Economy and Informatization published the 2018 Shanghai Municipality Innovative Product Recommendation List (“the Recommendation List”). The Castor™ Branched Aortic Stent-Graft System ("Castor™"), which was independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd. (Endovastec™), was granted entries into the list. 

The Recommendation List was compiled under the leadership of Shanghai Municipal Commission of Economy and Informatization. It aims to promote the industry transformation and upgrade of Shanghai and the innovation-driven development of the corporations, so as to develop the new economy, cultivate the new momentum, support Shanghai’s implementation of the innovation –driven development strategy, and build a science & technology and innovation center with global influence. A total of 68 products have entered the Recommendation List, all of which are major innovative products in Shanghai with self-owned intellectual property, economic potentials and good market prospects. The products can also enter the government procurement system, which will encourage and support the research and application of innovative products. The entries into the Recommendation List of Castor™ will become conducive to promoting the commercialization and industrialization of the products, and bring about new driving force to the process.

Castor™ is the world’s first stent graft that delivers endovascular reconstruction of aorta and aortic arch branches through minimally invasive treatment. The unique unibody design is applicable to all kinds of arch anatomies. The main body and branched stent are stitched together, delivered and deployed all at one time. It creatively solves the challenges of delivery and positioning for unibody branched stent and brings about the advantages of low endoleak rate and unobstructed branch, which can not only reduce surgical trauma but also increase surgical safety.